# Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure

## TL;DR

This paper explores how liver disease and metabolic issues change after curing Hepatitis C virus infection.

## Contribution

The study highlights the evolution of cardiometabolic risk factors after Hepatitis C virus eradication.

## Key findings

- Hepatic steatosis is common in chronic Hepatitis C patients due to insulin resistance or viral genotype.
- Curing Hepatitis C with DAAs impacts cardiometabolic risk factors and steatotic liver disease.
- Managing both infectious and metabolic disorders improves patient outcomes after Hepatitis C cure.

## Abstract

Hepatitis C virus (HCV) infection is an infectious disease carrying a high risk of metabolic disorders. Chronic HCV (CHC) patients can possess extrahepatic manifestations such as diabetes, steatotic liver disease (SLD), and other metabolic alterations. Hepatic steatosis, which is triggered by insulin resistance or the direct insult of a specific genotype, is commonly observed in CHC. The changes in SLD after HCV eradication by direct‐acting antivirals (DAAs) present a significant impact on patient outcomes. We reviewed the changes in cardiometabolic risk factors (CMRFs) and the evolution of CMRFs items in CHC patients with SLD after HCV cure. The reassessment of CMRFs after the successful eradication of HCV is an essential task for primary care providers. CHC patients could benefit from appropriate management of both infectious and metabolic disorders in terms of liver and nonliver related outcomes.